Strong pipeline of innovative I-O/cancer therapeutics

One of the most promising areas of medical innovation in the next five years is immuno-oncology (I-O)/cancer therapeutics represent, fundamentally transforming how cancer is treated, according to a survey conducted by pharma analytics company GlobalData.

In a recent GlobalData’s survey, “The State of the Biopharmaceutical Industry - 2025,” the largest proportion (41%) of surveyed pharmaceutical industry professionals indicated that the immuno-oncology/cancer therapeutics present the strongest innovation pipeline in the next five years.

“Advancements in immunotherapy such as checkpoint inhibitors, CAR-T cell therapies, cancer vaccines, etc, are revolutionizing the way cancer is treated, and as these therapies evolve, they may lead to more effective and personalized treatments. Further to this, high unmet needs in cancer with many types of indications lacking effective treatments are driving and will continue to drive the innovation in immuno-oncology/ cancer therapeutics,” commented Urte Jakimavicute, senior director of market research and strategic intelligence in the healthcare division at GlobalData.